AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Upcroft, J. A.
Right arrow Articles by Vanelle, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Upcroft, J. A.
Right arrow Articles by Vanelle, P.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2006, p. 344-347, Vol. 50, No. 1
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.1.344-347.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

5-Nitroimidazole Drugs Effective against Metronidazole-Resistant Trichomonas vaginalis and Giardia duodenalis

Jacqueline A. Upcroft,1* Linda A. Dunn,1 Janelle M. Wright,1,2 Kamel Benakli,3 Peter Upcroft,1 and Patrice Vanelle3

Queensland Institute of Medical Research and ACITHN, 300 Herston Rd., Brisbane, Queensland 4006, Australia,1 School of Population Health, University of Queensland, Brisbane, Queensland 4072, Australia,2 Laboratoire de Chimie Organique Pharmaceutique, LCOP-UMR CNRS 6517, Université de la Méditerranée, Faculté de Pharmacie, 27 Bd. J Moulin, 13385 Marseille Cedex 05, France3

Received 1 June 2005/ Returned for modification 22 June 2005/ Accepted 12 October 2005

Metronidazole (Mz)-resistant Giardia and Trichomonas were inhibited by 1 of 30 new 5-nitroimidazole drugs. Another five drugs were effective against some but not all of the Mz-resistant parasites. This study provides the incentive for the continued design of 5-nitroimidazole drugs to bypass cross-resistance among established 5-nitromidazole antiparasitic drugs.


* Corresponding author. Mailing address: The Queensland Institute of Medical Research, P.O. Royal Brisbane Hospital, Brisbane, Queensland 4029, Australia. Phone: 61 7 3362 0369. Fax: 61 7 3362 0105. E-mail: Jacqui.Upcroft{at}qimr.edu.au.


Antimicrobial Agents and Chemotherapy, January 2006, p. 344-347, Vol. 50, No. 1
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.1.344-347.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2006 by the American Society for Microbiology. All rights reserved.